Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Myasthenia Gravis ll: Pathophysiology

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Disorders of the Skeletal Muscle

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...

Skeletal Muscle Relaxants: Adverse Effects

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Chronic eosinophilic pneumonia.

Journal of insurance medicine (New York, N.Y.)·2008

Same author

Cranial artery dissection.

Journal of insurance medicine (New York, N.Y.)·2006

Same author

Autoimmune hepatitis.

Journal of insurance medicine (New York, N.Y.)·2004

Same author

Cystic fibrosis--a genetic dilemma.

Journal of insurance medicine (New York, N.Y.)·2004

Same journal

Creating Evidence-Based Ratings and Life Expectancies Medical Impairments.

Journal of insurance medicine (New York, N.Y.)·2026

Same journal

The Smoking Dilemma: A Technical Deep Dive.

Journal of insurance medicine (New York, N.Y.)·2026

Same journal

Biological Clocks: Ready for Prime Time?

Journal of insurance medicine (New York, N.Y.)·2026

Same journal

GLP-1 Therapies and Mortality Risk: Implications for Life Insurers.

Journal of insurance medicine (New York, N.Y.)·2026

Same journal

Identifying Benzodiazepine Abuse: A Report of 3 Cases.

Journal of insurance medicine (New York, N.Y.)·2026

Same journal

Between Fear and Adoption: The AI Paradox in Medico-Legal Practice Among National Insurance Physicians.

Journal of insurance medicine (New York, N.Y.)·2026

See all related articles

Search research articles

Related Experiment Videos

Statin induced myopathy.

Robert E Frank¹

¹Union Central Life Ins. Co., 1987 Waycross Road, Cincinnati, OH 45240, USA. rfrank@unificompanies.com

Journal of Insurance Medicine (New York, N.Y.)

|October 23, 2009

Summary

This summary is machine-generated.

Statin medications are generally safe for preventing cardiovascular events but can rarely cause muscle damage. If myopathy occurs, switching to a different statin may resolve the issue.

Related Experiment Videos

Area of Science:

Pharmacology
Cardiology
Toxicology

Background:

Statins are primary agents for cardiovascular event risk reduction.
While generally safe, statins can induce skeletal muscle toxicity (myopathy).
Statin-induced myopathy ranges from mild symptoms to severe myositis.

Observation:

Statin myopathy typically presents with muscle pain and weakness, often with normal creatine kinase (CK) levels.
Rarely, severe myositis can manifest with significant CK elevations.
Individual statins possess distinct pharmacological properties.

Findings:

Statin-induced myopathy is a known adverse effect.
Symptomatic relief is often achievable by substituting one statin for another.
Pharmacological differences between statins influence myopathy risk and management.

Implications:

Understanding statin pharmacology is crucial for managing potential myotoxicity.
Personalized statin selection can mitigate skeletal muscle side effects.
Further research into mechanisms of statin-induced myopathy is warranted.